{"protocolSection":{"identificationModule":{"nctId":"NCT03757130","orgStudyIdInfo":{"id":"20170139"},"organization":{"fullName":"Amgen","class":"INDUSTRY"},"briefTitle":"Multiple Ascending Dose Study of AMG 598 in Adults With Obesity","officialTitle":"A Phase 1b, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 598 in Subjects With Obesity"},"statusModule":{"statusVerifiedDate":"2022-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2018-11-26","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2019-12-16","type":"ACTUAL"},"completionDateStruct":{"date":"2019-12-16","type":"ACTUAL"},"studyFirstSubmitDate":"2018-11-27","studyFirstSubmitQcDate":"2018-11-27","studyFirstPostDateStruct":{"date":"2018-11-28","type":"ACTUAL"},"resultsFirstSubmitDate":"2022-11-04","resultsFirstSubmitQcDate":"2022-11-04","resultsFirstPostDateStruct":{"date":"2023-09-14","type":"ACTUAL"},"lastUpdateSubmitDate":"2022-11-04","lastUpdatePostDateStruct":{"date":"2023-09-14","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Amgen","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The main objective of this study is to assess the safety and tolerability of multiple doses of AMG 598 administered alone or in combination with liraglutide in adults with obesity."},"conditionsModule":{"conditions":["Obesity"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"OTHER","maskingInfo":{"masking":"DOUBLE","maskingDescription":"Double-blind study","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":50,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for a total of 3 doses.","interventionNames":["Drug: Placebo"]},{"label":"Placebo + Liraglutide","type":"ACTIVE_COMPARATOR","description":"Participants received placebo subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5.","interventionNames":["Drug: Placebo","Drug: Liraglutide"]},{"label":"AMG 598 70 mg","type":"EXPERIMENTAL","description":"Participants received 70 mg AMG 598 by subcutaneous injection once every 4 weeks (Q4W) for a total of 3 doses.","interventionNames":["Drug: AMG 598"]},{"label":"AMG 598 70 mg + Liraglutide","type":"EXPERIMENTAL","description":"Participants received 70 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5.","interventionNames":["Drug: AMG 598","Drug: Liraglutide"]},{"label":"AMG 598 210 mg","type":"EXPERIMENTAL","description":"Participants received 210 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses.","interventionNames":["Drug: AMG 598"]},{"label":"AMG 598 210 mg + Liraglutide","type":"EXPERIMENTAL","description":"Participants received 210 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5.","interventionNames":["Drug: AMG 598","Drug: Liraglutide"]},{"label":"AMG 598 420 mg","type":"EXPERIMENTAL","description":"Participants received 420 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses.","interventionNames":["Drug: AMG 598"]},{"label":"AMG 598 420 mg + Liraglutide","type":"EXPERIMENTAL","description":"Participants received 420 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5.","interventionNames":["Drug: AMG 598","Drug: Liraglutide"]}],"interventions":[{"type":"DRUG","name":"AMG 598","description":"AMG 598 administered by subcutaneous injection","armGroupLabels":["AMG 598 210 mg","AMG 598 210 mg + Liraglutide","AMG 598 420 mg","AMG 598 420 mg + Liraglutide","AMG 598 70 mg","AMG 598 70 mg + Liraglutide"]},{"type":"DRUG","name":"Placebo","description":"Placebo matching to AMG 598 administered by subcutaneous injection","armGroupLabels":["Placebo","Placebo + Liraglutide"]},{"type":"DRUG","name":"Liraglutide","description":"Liraglutide administered by subcutaneous injection. The starting dose is 0.6 mg/day, and increased by 0.6 mg/day dose increment every 7 days, up to the full dosage of 3.0 mg/day by week 5.","armGroupLabels":["AMG 598 210 mg + Liraglutide","AMG 598 420 mg + Liraglutide","AMG 598 70 mg + Liraglutide","Placebo + Liraglutide"],"otherNames":["Saxenda®"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Treatment-emergent Adverse Events","description":"The investigator assessed the severity of each adverse event reported during the study. The assessment was based on the Amgen Standard Grading Scale:\n\nMild: Aware of sign or symptom, but easily tolerated. Moderate: Discomfort enough to cause interference with usual activity. Severe: Incapacitating with inability to work or do usual activity.\n\nA Serious adverse event is defined as any untoward medical occurrence that, met at least 1 of the following serious criteria\n\n* Death;\n* Was life-threatening;\n* Required in-patient hospitalization or prolongation of existing hospitalization;\n* Resulted in persistent or significant disability/incapacity;\n* Was a congenital anomaly/birth defect;\n* Other medically important serious event.\n\nThe investigator also assessed whether each adverse event was related to study drug administration based on clinical judgement.","timeFrame":"207 days"},{"measure":"Number of Participants With TEAEs Due to Laboratory, Electrocardiogram, and Vital Sign Findings","description":"TEAEs due to laboratory, electrocardiogram (ECG) and vital sign findings include any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or electrocardiogram, or vital signs measurements, including those that worsened from baseline, that were considered clinically significant in the medical and scientific judgment of the investigator (ie, not related to progression of underlying disease).","timeFrame":"207 days"}],"secondaryOutcomes":[{"measure":"Maximum Observed Concentration (Cmax) of AMG 598 After Subcutaneous Injection on Day 1 and Day 57","description":"Serum concentrations of AMG 598 were determined using a validated electrochemiluminescence-based method. The lower limit of quantitation was 50.0 ng/mL.","timeFrame":"Day 1, predose, and days 6, 8, 15, 22, and 29; Day 57 predose and days 62, 64, 71, 85, 99, 113, 127, 169, and 207"},{"measure":"Time to Maximum Observed Concentration (Tmax) of AMG 598 After Subcutaneous Injection on Day 1 and Day 57","description":"Serum concentrations of AMG 598 were determined using a validated electrochemiluminescence-based method. The lower limit of quantitation was 50.0 ng/mL.","timeFrame":"Day 1, predose, and days 6, 8, 15, 22, and 29; Day 57 predose and days 62, 64, 71, 85, 99, 113, 127, 169, and 207"},{"measure":"Dose-normalized Cmax of AMG 598 After Subcutaneous Injection on Day 1 and Day 57","description":"Serum concentrations of AMG 598 were determined using a validated electrochemiluminescence-based method. The lower limit of quantitation was 50.0 ng/mL.","timeFrame":"Day 1, predose, and days 6, 8, 15, 22, and 29; Day 57 predose and days 62, 64, 71, 85, 99, 113, 127, 169, and 207"},{"measure":"Area Under the Concentration-time Curve From Time 0 to 28 Days (AUC0-28) for AMG 598 After Subcutaneous Injection on Day 1 and Day 57","description":"Serum concentrations of AMG 598 were determined using a validated electrochemiluminescence-based method. The lower limit of quantitation was 50.0 ng/mL.","timeFrame":"Day 1, predose, and days 6, 8, 15, 22, and 29; Day 57 predose and days 62, 64, 71, and 85"},{"measure":"Dose-normalized AUC0-28 for AMG 598 After Subcutaneous Injection on Day 1 and Day 57","description":"Serum concentrations of AMG 598 were determined using a validated electrochemiluminescence-based method. The lower limit of quantitation was 50.0 ng/mL.","timeFrame":"Day 1, predose, and days 6, 8, 15, 22, and 29; Day 57 predose and days 62, 64, 71, and 85"},{"measure":"Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUClast) of AMG 598 After Subcutaneous Injection on Day 57","description":"Serum concentrations of AMG 598 were determined using a validated electrochemiluminescence-based method. The lower limit of quantitation was 50.0 ng/mL.","timeFrame":"Day 57 predose and days 62, 64, 71, 85, 99, 113, 127, 169, and 207"},{"measure":"Accumulation Ratio (AR) for Cmax of AMG 598 After Subcutaneous Injection on Day 1 and Day 57","description":"Serum concentrations of AMG 598 were determined using a validated electrochemiluminescence-based method. The lower limit of quantitation was 50.0 ng/mL.\n\nAccumulation ratio for Cmax = Day 57 Cmax / Day 1 Cmax.","timeFrame":"Day 1, predose, and days 6, 8, 15, 22, and 29; Day 57 predose and days 62, 64, 71, 85, 99, 113, 127, 169, and 207"},{"measure":"Accumulation Ratio of AUC0-28 for AMG 598 After Subcutaneous Injection on Day 1 and Day 57","description":"Serum concentrations of AMG 598 were determined using a validated electrochemiluminescence-based method. The lower limit of quantitation was 50.0 ng/mL.\n\nThe accumulation ratio for AUC0-28 = Day 57 AUC0-28 / Day 1 AUC0-28.","timeFrame":"Day 1, predose, and days 6, 8, 15, 22, and 29; Day 57 predose and days 62, 64, 71, and 85"},{"measure":"Terminal Half-life (T1/2,z) of AMG 598 After Subcutaneous Injection on Day 57","description":"Serum concentrations of AMG 598 were determined using a validated electrochemiluminescence-based method. The lower limit of quantitation was 50.0 ng/mL.","timeFrame":"Day 57 predose and days 62, 64, 71, 85, 99, 113, 127, 169, and 207"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men and women with ages between 18 and 65 years old, inclusive, at time of signing consent\n* Body mass index (BMI) between greater than or equal to 30.0 kg/m\\^2 and less than or equal to 40.0 kg/m\\^2 at screening\n* Except for obesity, otherwise healthy or medically stable per protocol\n* Have a stable body weight defined as less than 5 kg self-reported change during the previous 8 weeks prior to screening\n* Other Inclusion criteria may apply\n* Stable on liraglutide, depending on cohort\n\nExclusion Criteria:\n\n* History or clinical evidence of diabetes\n* Inadequate organ function at screening\n* Currently receiving treatment in another investigational device or drug study\n* Women who are pregnant/lactating/breastfeeding or who plan to become pregnant/breastfeed while on study through 5 months after receiving the last dose of investigational product\n* History or evidence of a clinically significant disorder, condition or disease that would pose a risk to subject safety or interfere with the study evaluation, procedures or completion\n* A family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2; a personal history of non-familial medullary thyroid carcinoma; confirmed chronic pancreatitis or idiopathic acute pancreatitis, or gallbladder disease (ie, cholelithiasis or cholecystitis) not treated with cholecystectomy, for cohorts receiving liraglutide\n* History of major depressive disorder\n* Other Exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"MD","affiliation":"Amgen","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"William D Summers MD LLC","city":"Birmingham","state":"Alabama","zip":"35235","country":"United States","geoPoint":{"lat":33.52066,"lon":-86.80249}},{"facility":"Orange County Research Center","city":"Tustin","state":"California","zip":"92780","country":"United States","geoPoint":{"lat":33.74585,"lon":-117.82617}},{"facility":"QPS Miami Research Associates","city":"South Miami","state":"Florida","zip":"33143","country":"United States","geoPoint":{"lat":25.7076,"lon":-80.29338}},{"facility":"Dallas Diabetes and Endocrine Center","city":"Dallas","state":"Texas","zip":"75230","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}}]},"referencesModule":{"seeAlsoLinks":[{"label":"AmgenTrials clinical trials website","url":"http://www.amgentrials.com"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request","infoTypes":["STUDY_PROTOCOL","SAP","ICF","CSR"],"timeFrame":"Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.","accessCriteria":"Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.","url":"http://www.amgen.com/datasharing"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Eligible participants were randomized to one of six treatment cohorts. Within each cohort participants were randomly assigned in a 3:1 ratio to receive either AMG 598 or placebo.","recruitmentDetails":"This study was conducted at 2 centers in the United States.","groups":[{"id":"FG000","title":"Placebo","description":"Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for a total of 3 doses."},{"id":"FG001","title":"Placebo + Liraglutide","description":"Participants received placebo subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."},{"id":"FG002","title":"AMG 598 70 mg","description":"Participants received 70 mg AMG 598 by subcutaneous injection once every 4 weeks (Q4W) for a total of 3 doses."},{"id":"FG003","title":"AMG 598 70 mg + Liraglutide","description":"Participants received 70 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."},{"id":"FG004","title":"AMG 598 210 mg","description":"Participants received 210 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses."},{"id":"FG005","title":"AMG 598 210 mg + Liraglutide","description":"Participants received 210 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."},{"id":"FG006","title":"AMG 598 420 mg","description":"Participants received 420 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses."},{"id":"FG007","title":"AMG 598 420 mg + Liraglutide","description":"Participants received 420 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"8"},{"groupId":"FG004","numSubjects":"6"},{"groupId":"FG005","numSubjects":"6"},{"groupId":"FG006","numSubjects":"6"},{"groupId":"FG007","numSubjects":"6"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"7"},{"groupId":"FG004","numSubjects":"6"},{"groupId":"FG005","numSubjects":"6"},{"groupId":"FG006","numSubjects":"5"},{"groupId":"FG007","numSubjects":"5"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"1"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All enrolled participants","groups":[{"id":"BG000","title":"Placebo","description":"Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for a total of 3 doses."},{"id":"BG001","title":"Placebo + Liraglutide","description":"Participants received placebo subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."},{"id":"BG002","title":"AMG 598 70 mg","description":"Participants received 70 mg AMG 598 by subcutaneous injection once every 4 weeks (Q4W) for a total of 3 doses."},{"id":"BG003","title":"AMG 598 70 mg + Liraglutide","description":"Participants received 70 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."},{"id":"BG004","title":"AMG 598 210 mg","description":"Participants received 210 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses."},{"id":"BG005","title":"AMG 598 210 mg + Liraglutide","description":"Participants received 210 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."},{"id":"BG006","title":"AMG 598 420 mg","description":"Participants received 420 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses."},{"id":"BG007","title":"AMG 598 420 mg + Liraglutide","description":"Participants received 420 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."},{"id":"BG008","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"6"},{"groupId":"BG006","value":"6"},{"groupId":"BG007","value":"6"},{"groupId":"BG008","value":"50"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"47.2","spread":"11.0"},{"groupId":"BG001","value":"41.8","spread":"7.6"},{"groupId":"BG002","value":"41.7","spread":"11.3"},{"groupId":"BG003","value":"46.1","spread":"14.2"},{"groupId":"BG004","value":"50.3","spread":"7.8"},{"groupId":"BG005","value":"51.5","spread":"8.5"},{"groupId":"BG006","value":"44.5","spread":"10.9"},{"groupId":"BG007","value":"49.2","spread":"11.7"},{"groupId":"BG008","value":"46.5","spread":"10.6"}]}]}]},{"title":"Age, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"< 40 years","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"14"}]},{"title":"≥ 40 years","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"5"},{"groupId":"BG005","value":"5"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"5"},{"groupId":"BG008","value":"36"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"15"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"5"},{"groupId":"BG007","value":"5"},{"groupId":"BG008","value":"35"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"6"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"5"},{"groupId":"BG008","value":"41"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"9"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"1"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"10"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"5"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"5"},{"groupId":"BG007","value":"5"},{"groupId":"BG008","value":"39"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"}]}]}]},{"title":"Body Mass Index (BMI)","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kg/m²","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"34.22","spread":"2.61"},{"groupId":"BG001","value":"33.20","spread":"2.10"},{"groupId":"BG002","value":"34.62","spread":"2.92"},{"groupId":"BG003","value":"35.46","spread":"2.19"},{"groupId":"BG004","value":"34.43","spread":"3.37"},{"groupId":"BG005","value":"34.42","spread":"3.24"},{"groupId":"BG006","value":"32.77","spread":"3.04"},{"groupId":"BG007","value":"36.00","spread":"4.04"},{"groupId":"BG008","value":"34.43","spread":"2.92"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Treatment-emergent Adverse Events","description":"The investigator assessed the severity of each adverse event reported during the study. The assessment was based on the Amgen Standard Grading Scale:\n\nMild: Aware of sign or symptom, but easily tolerated. Moderate: Discomfort enough to cause interference with usual activity. Severe: Incapacitating with inability to work or do usual activity.\n\nA Serious adverse event is defined as any untoward medical occurrence that, met at least 1 of the following serious criteria\n\n* Death;\n* Was life-threatening;\n* Required in-patient hospitalization or prolongation of existing hospitalization;\n* Resulted in persistent or significant disability/incapacity;\n* Was a congenital anomaly/birth defect;\n* Other medically important serious event.\n\nThe investigator also assessed whether each adverse event was related to study drug administration based on clinical judgement.","populationDescription":"All participants who received at least 1 dose of study drug (AMG 598 or placebo) on day 1.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"207 days","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for a total of 3 doses."},{"id":"OG001","title":"Placebo + Liraglutide","description":"Participants received placebo subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."},{"id":"OG002","title":"AMG 598 70 mg","description":"Participants received 70 mg AMG 598 by subcutaneous injection once every 4 weeks (Q4W) for a total of 3 doses."},{"id":"OG003","title":"AMG 598 70 mg + Liraglutide","description":"Participants received 70 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."},{"id":"OG004","title":"AMG 598 210 mg","description":"Participants received 210 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses."},{"id":"OG005","title":"AMG 598 210 mg + Liraglutide","description":"Participants received 210 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."},{"id":"OG006","title":"AMG 598 420 mg","description":"Participants received 420 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses."},{"id":"OG007","title":"AMG 598 420 mg + Liraglutide","description":"Participants received 420 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"6"}]}],"classes":[{"title":"All treatment-emergent adverse events (TEAEs)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"4"}]}]},{"title":"Mild TEAEs","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"4"}]}]},{"title":"Moderate TEAEs","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"}]}]},{"title":"Severe TEAEs","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]},{"title":"Serious TEAEs","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]},{"title":"TEAE leading to discontinuation of AMG 598","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"}]}]},{"title":"TEAE leading to discontinuation of liraglutide","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"2"}]}]},{"title":"Life-threatening TEAEs","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]},{"title":"Fatal TEAEs","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]}]},{"type":"SECONDARY","title":"Maximum Observed Concentration (Cmax) of AMG 598 After Subcutaneous Injection on Day 1 and Day 57","description":"Serum concentrations of AMG 598 were determined using a validated electrochemiluminescence-based method. The lower limit of quantitation was 50.0 ng/mL.","populationDescription":"The pharmacokinetic (PK) analysis set included all participants for whom at least 1 PK parameter or endpoint could be adequately estimated. Participants with available data at each time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"µg/mL","timeFrame":"Day 1, predose, and days 6, 8, 15, 22, and 29; Day 57 predose and days 62, 64, 71, 85, 99, 113, 127, 169, and 207","groups":[{"id":"OG000","title":"AMG 598 70 mg","description":"Participants received 70 mg AMG 598 by subcutaneous injection once every 4 weeks (Q4W) for a total of 3 doses."},{"id":"OG001","title":"AMG 598 70 mg + Liraglutide","description":"Participants received 70 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."},{"id":"OG002","title":"AMG 598 210 mg","description":"Participants received 210 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses."},{"id":"OG003","title":"AMG 598 210 mg + Liraglutide","description":"Participants received 210 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."},{"id":"OG004","title":"AMG 598 420 mg","description":"Participants received 420 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses."},{"id":"OG005","title":"AMG 598 420 mg + Liraglutide","description":"Participants received 420 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"}]}],"classes":[{"title":"Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.83","spread":"1.67"},{"groupId":"OG001","value":"7.49","spread":"1.17"},{"groupId":"OG002","value":"21.5","spread":"5.43"},{"groupId":"OG003","value":"18.0","spread":"5.76"},{"groupId":"OG004","value":"51.1","spread":"9.70"},{"groupId":"OG005","value":"36.9","spread":"13.7"}]}]},{"title":"Day 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.07","spread":"1.91"},{"groupId":"OG001","value":"12.0","spread":"2.56"},{"groupId":"OG002","value":"45.4","spread":"12.5"},{"groupId":"OG003","value":"34.8","spread":"12.0"},{"groupId":"OG004","value":"93.2","spread":"18.2"},{"groupId":"OG005","value":"72.4","spread":"23.0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With TEAEs Due to Laboratory, Electrocardiogram, and Vital Sign Findings","description":"TEAEs due to laboratory, electrocardiogram (ECG) and vital sign findings include any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or electrocardiogram, or vital signs measurements, including those that worsened from baseline, that were considered clinically significant in the medical and scientific judgment of the investigator (ie, not related to progression of underlying disease).","populationDescription":"All participants who received at least 1 dose of study drug (AMG 598 or placebo) on day 1.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"207 days","groups":[{"id":"OG000","title":"Placebo","description":"Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for a total of 3 doses."},{"id":"OG001","title":"Placebo + Liraglutide","description":"Participants received placebo subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."},{"id":"OG002","title":"AMG 598 70 mg","description":"Participants received 70 mg AMG 598 by subcutaneous injection once every 4 weeks (Q4W) for a total of 3 doses."},{"id":"OG003","title":"AMG 598 70 mg + Liraglutide","description":"Participants received 70 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."},{"id":"OG004","title":"AMG 598 210 mg","description":"Participants received 210 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses."},{"id":"OG005","title":"AMG 598 210 mg + Liraglutide","description":"Participants received 210 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."},{"id":"OG006","title":"AMG 598 420 mg","description":"Participants received 420 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses."},{"id":"OG007","title":"AMG 598 420 mg + Liraglutide","description":"Participants received 420 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"6"}]}],"classes":[{"title":"Blood creatine phosphokinase increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]},{"title":"Electrocardiogram T wave abnormal","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"}]}]},{"title":"Hepatic enzyme increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"}]}]},{"title":"Lipase increased","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"}]}]},{"title":"Hypertension","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]}]},{"type":"SECONDARY","title":"Time to Maximum Observed Concentration (Tmax) of AMG 598 After Subcutaneous Injection on Day 1 and Day 57","description":"Serum concentrations of AMG 598 were determined using a validated electrochemiluminescence-based method. The lower limit of quantitation was 50.0 ng/mL.","populationDescription":"The PK analysis set; participants with available data at each time point","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"days","timeFrame":"Day 1, predose, and days 6, 8, 15, 22, and 29; Day 57 predose and days 62, 64, 71, 85, 99, 113, 127, 169, and 207","groups":[{"id":"OG000","title":"AMG 598 70 mg","description":"Participants received 70 mg AMG 598 by subcutaneous injection once every 4 weeks (Q4W) for a total of 3 doses."},{"id":"OG001","title":"AMG 598 70 mg + Liraglutide","description":"Participants received 70 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."},{"id":"OG002","title":"AMG 598 210 mg","description":"Participants received 210 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses."},{"id":"OG003","title":"AMG 598 210 mg + Liraglutide","description":"Participants received 210 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."},{"id":"OG004","title":"AMG 598 420 mg","description":"Participants received 420 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses."},{"id":"OG005","title":"AMG 598 420 mg + Liraglutide","description":"Participants received 420 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"}]}],"classes":[{"title":"Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","lowerLimit":"7.1","upperLimit":"14"},{"groupId":"OG001","value":"7.0","lowerLimit":"5.0","upperLimit":"21"},{"groupId":"OG002","value":"7.1","lowerLimit":"5.0","upperLimit":"13"},{"groupId":"OG003","value":"7.0","lowerLimit":"4.9","upperLimit":"14"},{"groupId":"OG004","value":"6.9","lowerLimit":"5.0","upperLimit":"7.3"},{"groupId":"OG005","value":"7.0","lowerLimit":"6.9","upperLimit":"14"}]}]},{"title":"Day 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.0","lowerLimit":"7.0","upperLimit":"14"},{"groupId":"OG001","value":"7.0","lowerLimit":"7.0","upperLimit":"7.0"},{"groupId":"OG002","value":"6.1","lowerLimit":"5.1","upperLimit":"7.0"},{"groupId":"OG003","value":"6.5","lowerLimit":"5.0","upperLimit":"8.0"},{"groupId":"OG004","value":"5.3","lowerLimit":"4.3","upperLimit":"8.0"},{"groupId":"OG005","value":"7.0","lowerLimit":"7.0","upperLimit":"11"}]}]}]},{"type":"SECONDARY","title":"Dose-normalized Cmax of AMG 598 After Subcutaneous Injection on Day 1 and Day 57","description":"Serum concentrations of AMG 598 were determined using a validated electrochemiluminescence-based method. The lower limit of quantitation was 50.0 ng/mL.","populationDescription":"The PK analysis set; participants with available data at each time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"µg/mL/mg","timeFrame":"Day 1, predose, and days 6, 8, 15, 22, and 29; Day 57 predose and days 62, 64, 71, 85, 99, 113, 127, 169, and 207","groups":[{"id":"OG000","title":"AMG 598 70 mg","description":"Participants received 70 mg AMG 598 by subcutaneous injection once every 4 weeks (Q4W) for a total of 3 doses."},{"id":"OG001","title":"AMG 598 70 mg + Liraglutide","description":"Participants received 70 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."},{"id":"OG002","title":"AMG 598 210 mg","description":"Participants received 210 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses."},{"id":"OG003","title":"AMG 598 210 mg + Liraglutide","description":"Participants received 210 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."},{"id":"OG004","title":"AMG 598 420 mg","description":"Participants received 420 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses."},{"id":"OG005","title":"AMG 598 420 mg + Liraglutide","description":"Participants received 420 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"}]}],"classes":[{"title":"Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0833","spread":"0.0239"},{"groupId":"OG001","value":"0.107","spread":"0.0167"},{"groupId":"OG002","value":"0.102","spread":"0.0258"},{"groupId":"OG003","value":"0.0856","spread":"0.0274"},{"groupId":"OG004","value":"0.122","spread":"0.0231"},{"groupId":"OG005","value":"0.0879","spread":"0.0327"}]}]},{"title":"Day 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.130","spread":"0.0272"},{"groupId":"OG001","value":"0.172","spread":"0.0366"},{"groupId":"OG002","value":"0.216","spread":"0.0593"},{"groupId":"OG003","value":"0.168","spread":"0.0572"},{"groupId":"OG004","value":"0.222","spread":"0.0433"},{"groupId":"OG005","value":"0.172","spread":"0.05949"}]}]}]},{"type":"SECONDARY","title":"Area Under the Concentration-time Curve From Time 0 to 28 Days (AUC0-28) for AMG 598 After Subcutaneous Injection on Day 1 and Day 57","description":"Serum concentrations of AMG 598 were determined using a validated electrochemiluminescence-based method. The lower limit of quantitation was 50.0 ng/mL.","populationDescription":"The PK analysis set; participants with available data at each time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"days*µg/mL","timeFrame":"Day 1, predose, and days 6, 8, 15, 22, and 29; Day 57 predose and days 62, 64, 71, and 85","groups":[{"id":"OG000","title":"AMG 598 70 mg","description":"Participants received 70 mg AMG 598 by subcutaneous injection once every 4 weeks (Q4W) for a total of 3 doses."},{"id":"OG001","title":"AMG 598 70 mg + Liraglutide","description":"Participants received 70 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."},{"id":"OG002","title":"AMG 598 210 mg","description":"Participants received 210 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses."},{"id":"OG003","title":"AMG 598 210 mg + Liraglutide","description":"Participants received 210 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."},{"id":"OG004","title":"AMG 598 420 mg","description":"Participants received 420 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses."},{"id":"OG005","title":"AMG 598 420 mg + Liraglutide","description":"Participants received 420 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"}]}],"classes":[{"title":"Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"139","spread":"19.6"},{"groupId":"OG001","value":"147","spread":"21.8"},{"groupId":"OG002","value":"495","spread":"72.7"},{"groupId":"OG003","value":"366","spread":"101"},{"groupId":"OG004","value":"1080","spread":"225"},{"groupId":"OG005","value":"763","spread":"285"}]}]},{"title":"Day 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"215","spread":"45.3"},{"groupId":"OG001","value":"276","spread":"57.6"},{"groupId":"OG002","value":"964","spread":"203"},{"groupId":"OG003","value":"749","spread":"254"},{"groupId":"OG004","value":"1990","spread":"341"},{"groupId":"OG005","value":"1610","spread":"511"}]}]}]},{"type":"SECONDARY","title":"Dose-normalized AUC0-28 for AMG 598 After Subcutaneous Injection on Day 1 and Day 57","description":"Serum concentrations of AMG 598 were determined using a validated electrochemiluminescence-based method. The lower limit of quantitation was 50.0 ng/mL.","populationDescription":"The PK analysis set; participants with available data at each time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"days*µg/mL/mg","timeFrame":"Day 1, predose, and days 6, 8, 15, 22, and 29; Day 57 predose and days 62, 64, 71, and 85","groups":[{"id":"OG000","title":"AMG 598 70 mg","description":"Participants received 70 mg AMG 598 by subcutaneous injection once every 4 weeks (Q4W) for a total of 3 doses."},{"id":"OG001","title":"AMG 598 70 mg + Liraglutide","description":"Participants received 70 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."},{"id":"OG002","title":"AMG 598 210 mg","description":"Participants received 210 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses."},{"id":"OG003","title":"AMG 598 210 mg + Liraglutide","description":"Participants received 210 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."},{"id":"OG004","title":"AMG 598 420 mg","description":"Participants received 420 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses."},{"id":"OG005","title":"AMG 598 420 mg + Liraglutide","description":"Participants received 420 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"6"}]}],"classes":[{"title":"Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.98","spread":"0.279"},{"groupId":"OG001","value":"2.10","spread":"0.311"},{"groupId":"OG002","value":"2.36","spread":"0.346"},{"groupId":"OG003","value":"1.74","spread":"0.480"},{"groupId":"OG004","value":"2.57","spread":"0.535"},{"groupId":"OG005","value":"1.82","spread":"0.680"}]}]},{"title":"Day 57","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"5"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.07","spread":"0.647"},{"groupId":"OG001","value":"3.94","spread":"0.823"},{"groupId":"OG002","value":"4.59","spread":"0.966"},{"groupId":"OG003","value":"3.57","spread":"1.21"},{"groupId":"OG004","value":"4.75","spread":"0.812"},{"groupId":"OG005","value":"3.84","spread":"1.22"}]}]}]},{"type":"SECONDARY","title":"Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUClast) of AMG 598 After Subcutaneous Injection on Day 57","description":"Serum concentrations of AMG 598 were determined using a validated electrochemiluminescence-based method. The lower limit of quantitation was 50.0 ng/mL.","populationDescription":"The PK analysis set; participants with available data for AUClast.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"days*µg/mL","timeFrame":"Day 57 predose and days 62, 64, 71, 85, 99, 113, 127, 169, and 207","groups":[{"id":"OG000","title":"AMG 598 70 mg","description":"Participants received 70 mg AMG 598 by subcutaneous injection once every 4 weeks (Q4W) for a total of 3 doses."},{"id":"OG001","title":"AMG 598 70 mg + Liraglutide","description":"Participants received 70 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."},{"id":"OG002","title":"AMG 598 210 mg","description":"Participants received 210 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses."},{"id":"OG003","title":"AMG 598 210 mg + Liraglutide","description":"Participants received 210 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."},{"id":"OG004","title":"AMG 598 420 mg","description":"Participants received 420 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses."},{"id":"OG005","title":"AMG 598 420 mg + Liraglutide","description":"Participants received 420 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"5"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"458","spread":"102"},{"groupId":"OG001","value":"612","spread":"129"},{"groupId":"OG002","value":"2130","spread":"334"},{"groupId":"OG003","value":"1570","spread":"462"},{"groupId":"OG004","value":"4060","spread":"1610"},{"groupId":"OG005","value":"3060","spread":"920"}]}]}]},{"type":"SECONDARY","title":"Accumulation Ratio (AR) for Cmax of AMG 598 After Subcutaneous Injection on Day 1 and Day 57","description":"Serum concentrations of AMG 598 were determined using a validated electrochemiluminescence-based method. The lower limit of quantitation was 50.0 ng/mL.\n\nAccumulation ratio for Cmax = Day 57 Cmax / Day 1 Cmax.","populationDescription":"The PK analysis set; participants with available data at both time points.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ratio","timeFrame":"Day 1, predose, and days 6, 8, 15, 22, and 29; Day 57 predose and days 62, 64, 71, 85, 99, 113, 127, 169, and 207","groups":[{"id":"OG000","title":"AMG 598 70 mg","description":"Participants received 70 mg AMG 598 by subcutaneous injection once every 4 weeks (Q4W) for a total of 3 doses."},{"id":"OG001","title":"AMG 598 70 mg + Liraglutide","description":"Participants received 70 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."},{"id":"OG002","title":"AMG 598 210 mg","description":"Participants received 210 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses."},{"id":"OG003","title":"AMG 598 210 mg + Liraglutide","description":"Participants received 210 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."},{"id":"OG004","title":"AMG 598 420 mg","description":"Participants received 420 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses."},{"id":"OG005","title":"AMG 598 420 mg + Liraglutide","description":"Participants received 420 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"5"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.62","spread":"0.394"},{"groupId":"OG001","value":"1.70","spread":"0.237"},{"groupId":"OG002","value":"2.12","spread":"0.251"},{"groupId":"OG003","value":"1.92","spread":"0.207"},{"groupId":"OG004","value":"1.83","spread":"0.138"},{"groupId":"OG005","value":"2.13","spread":"0.418"}]}]}]},{"type":"SECONDARY","title":"Accumulation Ratio of AUC0-28 for AMG 598 After Subcutaneous Injection on Day 1 and Day 57","description":"Serum concentrations of AMG 598 were determined using a validated electrochemiluminescence-based method. The lower limit of quantitation was 50.0 ng/mL.\n\nThe accumulation ratio for AUC0-28 = Day 57 AUC0-28 / Day 1 AUC0-28.","populationDescription":"The PK analysis set; participants with available data at both time points.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"ratio","timeFrame":"Day 1, predose, and days 6, 8, 15, 22, and 29; Day 57 predose and days 62, 64, 71, and 85","groups":[{"id":"OG000","title":"AMG 598 70 mg","description":"Participants received 70 mg AMG 598 by subcutaneous injection once every 4 weeks (Q4W) for a total of 3 doses."},{"id":"OG001","title":"AMG 598 70 mg + Liraglutide","description":"Participants received 70 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."},{"id":"OG002","title":"AMG 598 210 mg","description":"Participants received 210 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses."},{"id":"OG003","title":"AMG 598 210 mg + Liraglutide","description":"Participants received 210 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."},{"id":"OG004","title":"AMG 598 420 mg","description":"Participants received 420 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses."},{"id":"OG005","title":"AMG 598 420 mg + Liraglutide","description":"Participants received 420 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"4"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.74","spread":"0.480"},{"groupId":"OG001","value":"1.84","spread":"0.223"},{"groupId":"OG002","value":"2.09","spread":"0.254"},{"groupId":"OG003","value":"1.86","spread":"0.186"},{"groupId":"OG004","value":"1.96","spread":"0.177"},{"groupId":"OG005","value":"2.17","spread":"0.291"}]}]}]},{"type":"SECONDARY","title":"Terminal Half-life (T1/2,z) of AMG 598 After Subcutaneous Injection on Day 57","description":"Serum concentrations of AMG 598 were determined using a validated electrochemiluminescence-based method. The lower limit of quantitation was 50.0 ng/mL.","populationDescription":"The PK analysis set; participants with available data for T1/2,z","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"days","timeFrame":"Day 57 predose and days 62, 64, 71, 85, 99, 113, 127, 169, and 207","groups":[{"id":"OG000","title":"AMG 598 70 mg","description":"Participants received 70 mg AMG 598 by subcutaneous injection once every 4 weeks (Q4W) for a total of 3 doses."},{"id":"OG001","title":"AMG 598 70 mg + Liraglutide","description":"Participants received 70 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."},{"id":"OG002","title":"AMG 598 210 mg","description":"Participants received 210 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses."},{"id":"OG003","title":"AMG 598 210 mg + Liraglutide","description":"Participants received 210 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."},{"id":"OG004","title":"AMG 598 420 mg","description":"Participants received 420 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses."},{"id":"OG005","title":"AMG 598 420 mg + Liraglutide","description":"Participants received 420 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"5"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.2","spread":"3.04"},{"groupId":"OG001","value":"31.5","spread":"6.05"},{"groupId":"OG002","value":"35.2","spread":"5.86"},{"groupId":"OG003","value":"29.1","spread":"3.02"},{"groupId":"OG004","value":"35.8","spread":"3.21"},{"groupId":"OG005","value":"29.8","spread":"6.72"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From first dose of AMG 598/placebo through the end of study; 207 days.","eventGroups":[{"id":"EG000","title":"Placebo","description":"Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for a total of 3 doses.","deathsNumAffected":0,"deathsNumAtRisk":6,"seriousNumAffected":0,"seriousNumAtRisk":6,"otherNumAffected":1,"otherNumAtRisk":6},{"id":"EG001","title":"Placebo + Liraglutide","description":"Participants received placebo subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5.","deathsNumAffected":0,"deathsNumAtRisk":6,"seriousNumAffected":0,"seriousNumAtRisk":6,"otherNumAffected":6,"otherNumAtRisk":6},{"id":"EG002","title":"AMG 598 70 mg","description":"Participants received 70 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses.","deathsNumAffected":0,"deathsNumAtRisk":6,"seriousNumAffected":0,"seriousNumAtRisk":6,"otherNumAffected":4,"otherNumAtRisk":6},{"id":"EG003","title":"AMG 598 70 mg + Liraglutide","description":"Participants received 70 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5.","deathsNumAffected":0,"deathsNumAtRisk":8,"seriousNumAffected":0,"seriousNumAtRisk":8,"otherNumAffected":7,"otherNumAtRisk":8},{"id":"EG004","title":"AMG 598 210 mg","description":"Participants received 210 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses.","deathsNumAffected":0,"deathsNumAtRisk":6,"seriousNumAffected":0,"seriousNumAtRisk":6,"otherNumAffected":5,"otherNumAtRisk":6},{"id":"EG005","title":"AMG 598 210 mg + Liraglutide","description":"Participants received 210 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5.","deathsNumAffected":0,"deathsNumAtRisk":6,"seriousNumAffected":0,"seriousNumAtRisk":6,"otherNumAffected":6,"otherNumAtRisk":6},{"id":"EG006","title":"AMG 598 420 mg","description":"Participants received 420 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses.","deathsNumAffected":0,"deathsNumAtRisk":6,"seriousNumAffected":0,"seriousNumAtRisk":6,"otherNumAffected":0,"otherNumAtRisk":6},{"id":"EG007","title":"AMG 598 420 mg + Liraglutide","description":"Participants received 420 mg AMG 598 by subcutaneous injection once every 4 weeks for a total of 3 doses in addition to liraglutide administered by subcutaneous injection once a day for 12 weeks. The starting dose of liraglutide was 0.6 mg/day, increasing in increments of 0.6 mg/day every 7 days to reach the full dosage of 3 mg/day by week 5.","deathsNumAffected":0,"deathsNumAtRisk":6,"seriousNumAffected":0,"seriousNumAtRisk":6,"otherNumAffected":4,"otherNumAtRisk":6}],"otherEvents":[{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":1,"numAtRisk":6}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":2,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":1,"numAtRisk":6}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":2,"numAtRisk":6}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":0,"numAtRisk":6}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":2,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":0,"numAtRisk":6}]},{"term":"Eructation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":1,"numAtRisk":6}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":0,"numAtRisk":6}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":4,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":6},{"groupId":"EG003","numAffected":2,"numAtRisk":8},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":2,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":3,"numAtRisk":6}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":0,"numAtRisk":6}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":2,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":2,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":2,"numAtRisk":6}]},{"term":"Early satiety","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":2,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":1,"numAtRisk":6}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":1,"numAtRisk":6}]},{"term":"Injection site haematoma","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":0,"numAtRisk":6}]},{"term":"Injection site haemorrhage","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":1,"numAtRisk":6}]},{"term":"Injection site reaction","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":0,"numAtRisk":6}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":1,"numAtRisk":6}]},{"term":"Furuncle","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":0,"numAtRisk":6}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":0,"numAtRisk":6}]},{"term":"Gastroenteritis viral","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":0,"numAtRisk":6}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":1,"numAtRisk":6}]},{"term":"Tooth abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":0,"numAtRisk":6}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":6},{"groupId":"EG001","numAffected":2,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":6},{"groupId":"EG003","numAffected":2,"numAtRisk":8},{"groupId":"EG004","numAffected":3,"numAtRisk":6},{"groupId":"EG005","numAffected":4,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":2,"numAtRisk":6}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":0,"numAtRisk":6}]},{"term":"Viral infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":0,"numAtRisk":6}]},{"term":"Ligament sprain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":0,"numAtRisk":6}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":0,"numAtRisk":6}]},{"term":"Electrocardiogram T wave abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":1,"numAtRisk":6}]},{"term":"Hepatic enzyme increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":1,"numAtRisk":6}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":3,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":1,"numAtRisk":6}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":4,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":5,"numAtRisk":8},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":0,"numAtRisk":6}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":0,"numAtRisk":6}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":0,"numAtRisk":6}]},{"term":"Exostosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":0,"numAtRisk":6}]},{"term":"Pain in jaw","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":0,"numAtRisk":6}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":0,"numAtRisk":6}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":1,"numAtRisk":6},{"groupId":"EG005","numAffected":1,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":1,"numAtRisk":6}]},{"term":"Presyncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":0,"numAtRisk":6}]},{"term":"Pollakiuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":0,"numAtRisk":6}]},{"term":"Vulvovaginal pruritus","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":0,"numAtRisk":6}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":0,"numAtRisk":6}]},{"term":"Ecchymosis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":1,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":0,"numAtRisk":6}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":1,"numAtRisk":6}]},{"term":"Flushing","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":1,"numAtRisk":6},{"groupId":"EG002","numAffected":0,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":0,"numAtRisk":6}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":6},{"groupId":"EG001","numAffected":0,"numAtRisk":6},{"groupId":"EG002","numAffected":1,"numAtRisk":6},{"groupId":"EG003","numAffected":0,"numAtRisk":8},{"groupId":"EG004","numAffected":0,"numAtRisk":6},{"groupId":"EG005","numAffected":0,"numAtRisk":6},{"groupId":"EG006","numAffected":0,"numAtRisk":6},{"groupId":"EG007","numAffected":0,"numAtRisk":6}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication."},"pointOfContact":{"title":"Study Director","organization":"Amgen Inc.","email":"medinfo@amgen.com","phone":"866-572-6436"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2019-06-25","uploadDate":"2022-11-04T06:05","filename":"Prot_000.pdf","size":1608093},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2019-07-22","uploadDate":"2022-11-04T06:05","filename":"SAP_001.pdf","size":304336}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09"},"conditionBrowseModule":{"meshes":[{"id":"D009765","term":"Obesity"}],"ancestors":[{"id":"D050177","term":"Overweight"},{"id":"D044343","term":"Overnutrition"},{"id":"D009748","term":"Nutrition Disorders"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D001835","term":"Body Weight"},{"id":"D012816","term":"Signs and Symptoms"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069450","term":"Liraglutide"}],"ancestors":[{"id":"D052216","term":"Glucagon-Like Peptide 1"},{"id":"D004763","term":"Glucagon-Like Peptides"},{"id":"D052336","term":"Proglucagon"},{"id":"D005768","term":"Gastrointestinal Hormones"},{"id":"D006728","term":"Hormones"},{"id":"D006730","term":"Hormones, Hormone Substitutes, and Hormone Antagonists"}]}},"hasResults":true}